STAGE IVB BLADDER CANCER AJCC V8
Clinical trials for STAGE IVB BLADDER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IVB BLADDER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IVB BLADDER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for bladder cancer patients who Can't take chemo
Disease control OngoingThis study tests whether combining radiation therapy with immunotherapy drugs (durvalumab with or without tremelimumab) can help people with advanced bladder cancer who cannot or will not have chemotherapy. The trial includes 13 participants with cancer that has spread or cannot …
Matched conditions: STAGE IVB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Immunotherapy-Chemo combo targets tough neuroendocrine cancers
Disease control OngoingThis early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…
Matched conditions: STAGE IVB BLADDER CANCER AJCC V8
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Can a gene test tell who responds to immunotherapy for bladder cancer?
Knowledge-focused OngoingThis small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…
Matched conditions: STAGE IVB BLADDER CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC